Next Article in Journal
Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer
Next Article in Special Issue
Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
Previous Article in Journal
Immunological Distinctions between Acellular and Whole-Cell Pertussis Immunizations of Baboons Persist for at Least One Year after Acellular Vaccine Boosting
Review

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments

1
Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy
2
Institute of Dermatology, Catholic University, 00185 Rome, Italy
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 728; https://doi.org/10.3390/vaccines8040728
Received: 17 November 2020 / Revised: 30 November 2020 / Accepted: 1 December 2020 / Published: 2 December 2020
Chronic plaque psoriasis is an inflammatory skin disease affecting 2–3% of the general population. Approximately one-third of patients are candidates for systemic immunosuppressive treatments, such as synthetic or biological disease-modifying antirheumatic drugs, because of disease extensions, localization in sensitive or visible areas and/or resistance to topical treatments. These therapies have been associated with increased risk of infection, including upper respiratory tract viral infection. Psoriasis is frequently associated with cardio-metabolic comorbidities, such as obesity and diabetes, that are risk factors for poor prognosis in the case of coronavirus disease (COVID-19) pneumonia. A narrative review of the literature based on an electronic search of the PubMed® database was undertaken with the objective of investigating whether there is an increased risk of COVID-19 infection in psoriasis patients on systemic treatment. Original articles, such as case reports, published up to 1 November 2020 were included. There is no evidence that patients with moderate-to-severe psoriasis receiving systemic treatments, including biologics, have higher risk of SARS-CoV-2 infection and/or increased hospitalization and death related to COVID-19 compared to the general population. Several case reports described full recovery from COVID-19 with favorable outcomes in psoriasis patients who were being treated with synthetics or biologicals. Nonetheless, caution should be maintained in this setting, and more data are needed to draw definitive conclusions. View Full-Text
Keywords: psoriasis; Sars-CoV-2; COVID-19; biologics; synthetic and biological disease-modifying antirheumatic drugs (DMARDs) psoriasis; Sars-CoV-2; COVID-19; biologics; synthetic and biological disease-modifying antirheumatic drugs (DMARDs)
Show Figures

Figure 1

MDPI and ACS Style

Gisondi, P.; Bellinato, F.; Chiricozzi, A.; Girolomoni, G. The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. Vaccines 2020, 8, 728. https://doi.org/10.3390/vaccines8040728

AMA Style

Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G. The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. Vaccines. 2020; 8(4):728. https://doi.org/10.3390/vaccines8040728

Chicago/Turabian Style

Gisondi, Paolo, Francesco Bellinato, Andrea Chiricozzi, and Giampiero Girolomoni. 2020. "The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments" Vaccines 8, no. 4: 728. https://doi.org/10.3390/vaccines8040728

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop